{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:42:35Z","timestamp":1792687355516,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007911","name":"UCSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008091","name":"University of Rome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008091","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ejmech.2018.06.063","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T15:15:48Z","timestamp":1530198948000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents"],"prefix":"10.1016","volume":"156","author":[{"given":"Francesco","family":"Saccoliti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Noemi","family":"Madia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Tudino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pescatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Messore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2006-7005","authenticated-orcid":false,"given":"Luigi","family":"Scipione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"M\u00e4ser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Magalhaes","family":"Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth K.","family":"Jennings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa M.","family":"Podust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Costi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-7666","authenticated-orcid":false,"given":"Roberto","family":"Di Santo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.06.063_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fimmu.2017.00363","article-title":"The roles of mast cells in parasitic protozoan infections","volume":"8","author":"Lu","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib2","unstructured":"WHO, Fact Sheets Malaria. http:\/\/www.who.int\/mediacentre\/factsheets\/fs094\/en\/(accessed 13 April 2018)."},{"key":"10.1016\/j.ejmech.2018.06.063_bib3","unstructured":"WHO, World Malaria Report 2017 http:\/\/www.who.int\/malaria\/media\/world-malaria-report-2017\/en\/(accessed 13 April 2018)."},{"key":"10.1016\/j.ejmech.2018.06.063_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1473-3099(17)30048-8","article-title":"The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study","volume":"17","author":"Imwong","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.06.063_bib5","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2174\/0929867311320210005","article-title":"Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery","volume":"20","author":"Bernardes","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib6","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/molbev\/msg062","article-title":"Phylogeny of Trypanosomatidae and Bodonidae (Kinetoplastida) based on 18S rRNA: evidence for paraphyly of Trypanosoma and six other genera","volume":"20","author":"Hughes","year":"2003","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib7","unstructured":"WHO, Neglected Tropical Diseases. http:\/\/www.who.int\/neglected_diseases\/diseases\/en\/(accessed 13 April 2018)."},{"key":"10.1016\/j.ejmech.2018.06.063_bib8","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/bmb\/ldp046","article-title":"Neglected tropical diseases","volume":"93","author":"Feasey","year":"2010","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.ejmech.2018.06.063_bib9","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.06.063_bib10","author":"WHO"},{"key":"10.1016\/j.ejmech.2018.06.063_bib11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/14756366.2016.1250755","article-title":"Inhibition of Leishmania infantum trypanothione reductase by diaryl sulfide derivatives","volume":"32","author":"Saccoliti","year":"2017","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib12","unstructured":"WHO, Fact Sheets Chagas Disease. http:\/\/www.who.int\/mediacentre\/factsheets\/fs340\/en\/(accessed 13 April 2018)."},{"key":"10.1016\/j.ejmech.2018.06.063_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/jeu.12184","article-title":"Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives","volume":"62","author":"Urbina","year":"2015","journal-title":"J.\u00a0Eukaryot. Microbiol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib14","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"Molina","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.06.063_bib15","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMct1014204","article-title":"Antitrypanosomal therapy for chronic Chagas' disease","volume":"364","author":"Bern","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2018.06.063_bib16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/infdis\/jiv228","article-title":"VFV as a new effective CYP51 structure-derived drug candidate for Chagas disease and visceral leishmaniasis","volume":"212","author":"Lepesheva","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.06.063_bib17","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"van Griensven","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ejmech.2018.06.063_bib18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/anie.200300639","article-title":"Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia","volume":"44","author":"Krauth-Siegel","year":"2005","journal-title":"Angew Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2018.06.063_bib19","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2174\/156802611796575902","article-title":"Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis","volume":"11","author":"Lepesheva","year":"2011","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib20","first-page":"1","article-title":"Antiparasitic agents: new drugs on the horizon","volume":"14","author":"M\u00e4ser","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib21","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1021\/jm9004835","article-title":"Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania","volume":"52","author":"Cavalli","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1186\/2193-1801-3-679","article-title":"Interactions of antiparasitic sterols with sterol 14\u03b1-demethylase (CYP51) of human pathogens","volume":"3","author":"Warfield","year":"2014","journal-title":"SpringerPlus"},{"key":"10.1016\/j.ejmech.2018.06.063_bib23","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/gbe\/evp036","article-title":"Phylogenomics of sterol synthesis: insights into the origin, evolution, and diversity of a key eukaryotic feature","volume":"1","author":"Desmond","year":"2009","journal-title":"Genome Biol. Evol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.chembiol.2007.10.011","article-title":"Sterol 14alpha-demethylase as a potential target for antitrypanosomal therapy: enzyme inhibition and parasite cell growth","volume":"14","author":"Lepesheva","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib25","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2174\/15680266113139990125","article-title":"Recent developments in azole compounds as antibacterial and antifungal agents","volume":"13","author":"Peng","year":"2013","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib26","doi-asserted-by":"crossref","first-page":"15149","DOI":"10.1073\/pnas.2535442100","article-title":"A\u00a0class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents","volume":"100","author":"Buckner","year":"2003","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2018.06.063_bib27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1126\/science.273.5277.969","article-title":"Cure of short- and long-term experimental Chagas' disease using D0870","volume":"273","author":"Urbina","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.06.063_bib28","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.exppara.2005.08.006","article-title":"Antiproliferative and ultrastructural effects of BPQ-OH, a specific inhibitor of squalene synthase, on Leishmania amazonensis","volume":"111","author":"Rodrigues","year":"2005","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib29","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1128\/AAC.48.7.2379-2387.2004","article-title":"In\u00a0vitro and in\u00a0vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi","volume":"48","author":"Urbina","year":"2004","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.06.063_bib30","doi-asserted-by":"crossref","first-page":"11242","DOI":"10.1021\/cr5003134","article-title":"Drug strategies targeting CYP51 in neglected tropical diseases","volume":"114","author":"Choi","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.06.063_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0006132","article-title":"4-Aminopyridyl-based lead compounds targeting CYP51 prevent spontaneous parasite relapse in a chronic model and improve cardiac pathology in an acute model of Trypanosoma cruzi infection","volume":"11","author":"Calvet","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.06.063_bib32","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1128\/AAC.01294-15","article-title":"Maria de Nazar\u00e8 C. Soeiro, Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection","volume":"59","author":"Guedes-da-Silva","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.06.063_bib33","doi-asserted-by":"crossref","first-page":"e02098","DOI":"10.1128\/AAC.02098-16","article-title":"Antitrypanosomal activity of sterol 14\u03b1-demethylase (CYP51) inhibitors VNI and VFV in the Swiss mouse models of Chagas disease induced by the Trypanosoma cruzi Y strain","volume":"61","author":"Guedes-da-Silva","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.06.063_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejmech.2018.02.020","article-title":"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: in\u00a0vitro and in\u00a0vivo evaluation, binding mode prediction and SAR exploration","volume":"149","author":"Ferreira de Almeida Fiuza","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2018.06.063_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0074-02762009000900041","article-title":"Ergosterol biosynthesis and drug development for Chagas disease","volume":"104","author":"Urbina","year":"2009","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.ejmech.2018.06.063_bib36","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1038\/nature09224","article-title":"Chagas disease: pushing through the pipeline","volume":"465","author":"Clayton","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.06.063_bib37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0924-8579(02)00273-X","article-title":"In\u00a0vitro and in\u00a0vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease","volume":"21","author":"Urbina","year":"2003","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejmech.2018.06.063_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1087057114550585","article-title":"Chagas disease drug discovery: toward a new era","volume":"20","author":"Chatelain","year":"2015","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ejmech.2018.06.063_bib39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/QCO.0000000000000192","article-title":"The use of posaconazole against Chagas disease","volume":"28","author":"Molina","year":"2015","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.ejmech.2018.06.063_bib40","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Investigators. Stop-chagas, benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial","volume":"69","author":"Morillo","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib41","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jacc.2017.03.611","article-title":"Pharmacodynamics and follow-up period in the treatment of human trypanosoma cruzi infections with posaconazole","volume":"70","author":"Urbina","year":"2017","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib42","first-page":"148","article-title":"Novel in\u00a0vitro highly active antifungal agents with pyrrole and imidazole moieties","volume":"2","author":"Massa","year":"1992","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.ejmech.2018.06.063_bib43","first-page":"12","article-title":"Researches on antibacterial and antifungal agents. XV. 3-aryl-4-[\u03b1-(1H-imidazole-1-yl)benzyl]pyrroles with potent antifungal activity","volume":"1","author":"Massa","year":"1993","journal-title":"Eur. Bul. Drug. Res."},{"key":"10.1016\/j.ejmech.2018.06.063_bib44","first-page":"725","article-title":"Antifungal agents. III. Naphthyl and thienyl derivatives of 1H-imidazole-1-yl-4-phenyl-1H-pyrrol-3-ylmethane","volume":"48","author":"Massa","year":"1993","journal-title":"Il Farmaco"},{"key":"10.1016\/j.ejmech.2018.06.063_bib45","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1021\/jm00021a011","article-title":"Antifungal Agents. 9. 3-Aryl-4-[a-1(H-imidazole-l-yl)arylmethyl]pyrroles: a new class of potent anti-Candida Agents","volume":"38","author":"Artico","year":"1995","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/jm950385+","article-title":"Molecular modeling of azole antifungal agents active against Candida albicans. 1. A comparative molecular field analysis study","volume":"39","author":"Tafi","year":"1996","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0223-5234(97)87541-1","article-title":"Antifungal estrogen-like imidazoles. Synthesis and antifungal activities of thienyl and lH-pyrrolyl derivatives of 1-aryl-2-(lH-imidazole-1-yl)ethane","volume":"32","author":"Di Santo","year":"1997","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib48","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1021\/jm011087h","article-title":"Antifungal Agents. 10. New derivatives of 1-[(aryl)[4-aryl-1H-pyrrol-3-yl]methyl]-1H-imidazole, synthesis, anti-Candida activity, and quantitative structure-analysis relationship studies","volume":"45","author":"Tafi","year":"2002","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib49","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.1021\/jm048997u","article-title":"Antifungal Agents. 11. N-Substituted derivatives of 1-[(aryl)(4-aryl-1H-pyrrol-3-yl)methyl]-1H-imidazole: synthesis, anti-Candida activity, and QSAR studies","volume":"48","author":"Di Santo","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/md8010047","article-title":"Inhibitory activity of marine sponge-derived natural products against parasitic protozoa","volume":"8","author":"Orhan","year":"2010","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2018.06.063_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000651","article-title":"Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole","volume":"4","author":"Chen","year":"2010","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejmech.2018.06.063_bib52","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/cmi.12297","article-title":"Bioluminescence imaging of chronic Trypanosoma cruzi infections reveals tissue-specific parasite dynamics and heart disease in the absence of locally persistent infection","volume":"16","author":"Lewis","year":"2014","journal-title":"Cell Microbiol."},{"key":"10.1016\/j.ejmech.2018.06.063_bib53","doi-asserted-by":"crossref","first-page":"6989","DOI":"10.1021\/jm500448u","article-title":"4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in\u00a0vivo potency","volume":"57","author":"Calvet","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1590\/S0036-46652011000100005","article-title":"Disturbance in hemoglobin metabolism and in\u00a0vivo antimalarial activity of azole antimycotics","volume":"53","author":"Rodrigues","year":"2011","journal-title":"Rev. Inst. Med. Trop. Sao Paulo"},{"key":"10.1016\/j.ejmech.2018.06.063_bib55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/oxfordjournals.jbchem.a003119","article-title":"Effect of antifungal azoles on the heme detoxification system of malarial parasite","volume":"131","author":"Huy","year":"2002","journal-title":"J.\u00a0Biochem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib56","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejmech.2018.01.017","article-title":"In\u00a0vitro antiplasmodial efficacy of synthetic coumarin-triazole analogs","volume":"145","author":"Yadav","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bmc.2016.10.029","article-title":"Synthesis and evaluation of naphthyl bearing 1,2,3-triazole analogs as antiplasmodial agents, cytotoxicity and docking studies","volume":"25","author":"Balabadra","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib58","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejmech.2015.12.038","article-title":"Identification of \u03b2-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents","volume":"109","author":"Devender","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.06.063_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.abb.2010.12.008","article-title":"Spectroscopic features of cytochrome P450 reaction intermediates","volume":"507","author":"Luthra","year":"2011","journal-title":"Arch. Biochem. Biophys."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T16:39:17Z","timestamp":1568911157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418305543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":59,"alternative-id":["S0223523418305543"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.063","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.06.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}